abstract |
The present invention relates to a conditional bispecific redirected activated construct or COBRA, which is administered in an active prodrug format. After exposure to tumor protease, the construct is lysed and activated so that it can bind to tumor target antigen (TTA) and CD3, so T cells expressing CD3 are recruited into the tumor, causing treatment. |